SK hynix unveils record shareholder return policy, stock seen reaching 2.3 million won

This is on top of the 40 trillion won share buyback and cancellation plan the company previously announced.

SK hynix has said it will use at least 50% of its free cash flow (FCF) for shareholder returns, and this aggressive return policy is seen as the basis for JP Morgan's positive analysis.

"On top of the 40 trillion won share buyback and cancellation SK hynix announced recently, they have room to return an additional 180 trillion won to shareholders by 2027," said Shin Kwang-seop, gold manager at MBN.

This figure is derived by applying a return of at least 50% of free cash flow (FCF) to shareholders.

Specifically, the analysis presents a target price range of 2.15 million to 2.3 million won, implying roughly 35% upside from the current price. Shin Kwang-seop of MBN Gold stressed, "First, it has to reach 2.3 million won... Since they say they'll use more than 50% of the money they earn each year for share cancellations and dividends."

With the share price already up sharply, confirmation of next-quarter earnings guidance will likely be needed to build further upward momentum.

Nvidia's earnings release and guidance, scheduled for November 27 (Korea time), are expected to act as a key catalyst for SK hynix's stock. Shin Kwang-seop of MBN Gold said, "After it climbs up to here... it will move sideways here... On the 27th next week, Korea time. What's there? Nvidia's earnings announcement and guidance."

Moderna announced successful results from its Phase 3 cancer vaccine trial, signaling a possible shift in the cancer treatment market. The vaccine is known as a therapeutic cancer vaccine aimed at preventing recurrence and metastasis by using cells extracted from existing cancer patients.

The market is focusing on the possibility that Moderna's cancer vaccine could produce synergy when given in combination with Alteogen's Keytruda SC formulation. This suggests the combination could be effective in preventing cancer recurrence and metastasis after anticancer treatment. Shin Kwang-seop of MBN Gold explained, "This mRNA-based therapeutic cancer vaccine, what data does it show? It's a vaccine that extracts cells from patients who previously had cancer and can be used to prevent and, in a sense, treat it."

Despite the major positive news of Moderna's successful Phase 3 cancer vaccine trial, Alteogen's stock is still trading in a range. This suggests Alteogen needs to prove momentum of its own beyond the Moderna news.

Shin Kwang-seop of MBN Gold assessed the situation: "Today I thought Alteogen would hit a new high today... But even though everyone expected it, it went the other way. Even with this big positive news... it could move into a range here."

Alteogen therefore needs to meet investor expectations through its own technology and pipeline results rather than relying solely on external positive news to secure upward stock momentum.